ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Arch Biopartners to Proceed with Metablok Trial for COVID-19 americanpharmaceuticalreview
June 28, 2020Arch Biopartners announced the U.S. Food and Drug Administration (FDA) has granted permission to the Company to proceed with a Phase II trial in the U.S. for its lead drug Metablok (LSALT peptide) to prevent acute lung and kidney injury experienced by ... -
Arch Biopartners Expands Primary Endpoint of COVID-19 Trial americanpharmaceuticalreview
May 26, 2020Arch Biopartners has expanded the primary endpoint of the Phase II human trial for its lead drug LSALT peptide (Metablok) to prevent organ inflammation and injury experienced by patients with COVID-19.
Pharma Sources Insight January 2025
